Sera Prognostics (NASDAQ:SERA) Stock Price Down 3.4% – Here’s Why

Sera Prognostics, Inc. (NASDAQ:SERA) shares fell 3.4% during trading on Wednesday . The company traded as low as $1.97 and last traded at $2.01. Approximately 15,379 shares changed hands during trading, a decline of 43% from the average session volume of 26,750 shares. The stock had previously closed at $2.08.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Weiss Ratings cut Sera Prognostics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, July 31st. Craig Hallum assumed coverage on shares of Sera Prognostics in a research report on Thursday, June 4th. They issued a “buy” rating and a $6.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $5.50.

Sera Prognostics Price Performance

The stock has a 50 day moving average of $2.04 and a two-hundred day moving average of $2.04. The stock has a market capitalization of $78.11 million, a PE ratio of -2.96 and a beta of 0.98.

Sera Prognostics (NASDAQ:SERA) last issued its earnings results on Wednesday, August 12th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.03). The company had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.07 million. Sera Prognostics had a negative return on equity of 46.71% and a negative net margin of 47,475.72%. As a group, research analysts predict that Sera Prognostics, Inc. will post -0.62 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Zhenya Lindgardt sold 20,755 shares of Sera Prognostics stock in a transaction dated Tuesday, June 9th. The shares were sold at an average price of $2.08, for a total transaction of $43,170.40. Following the completion of the sale, the chief executive officer directly owned 871,999 shares in the company, valued at $1,813,757.92. The trade was a 2.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 27,755 shares of company stock worth $57,840. Company insiders own 11.30% of the company’s stock.

Institutional Trading of Sera Prognostics

Institutional investors have recently made changes to their positions in the stock. Arkadios Wealth Advisors purchased a new stake in Sera Prognostics during the first quarter worth approximately $25,000. Lido Advisors LLC purchased a new stake in Sera Prognostics during the 3rd quarter worth $68,000. Cetera Investment Advisers acquired a new stake in Sera Prognostics in the 4th quarter valued at $74,000. Qube Research & Technologies Ltd purchased a new position in Sera Prognostics in the second quarter valued at about $92,000. Finally, Two Sigma Investments LP purchased a new stake in shares of Sera Prognostics in the third quarter worth about $97,000. 54.64% of the stock is owned by hedge funds and other institutional investors.

Sera Prognostics Company Profile

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.